Does Lenzilumab Improve Survival in Patients With COVID-19 Pneumonia?
A phase 3 clinical trial evaluated the monoclonal antibody lenzilumab for improving survival without mechanical ventilation in COVID-19 pneumonia.
Sheila Jacobs
Contributing Writer https://www.infectiousdiseaseadvisor.com
Sheila Jacobs is the president of STJ Editorial Services. For more than 25 years, Sheila has been providing writing, fact-checking, and editorial services to numerous clients in the medical education, promotional, and managed care arenas, from the conceptual stage through completion of the final editorial product. Her focus has been in a diverse array of therapeutic areas.
